9月22日 - ** Vertex Pharmaceuticals（VRTX.O）股价上涨1.1%，至516.53美元
** 这家生物技术公司表示，其试验性药物 inaxaplin 在治疗 APOL1 介导的肾病患者 13 周后，使尿液中蛋白质含量（肾损伤的关键指标）降低了 42.7%
** 这种遗传性肾脏疾病主要影响非洲裔人群，可能导致肾功能衰竭；目前尚无获批的治疗方法
** 该公司称，该药物还使同时患有该疾病和2型糖尿病的患者的尿蛋白水平降低了17.3%
** 称伊纳萨普林总体安全且耐受性良好，未出现与治疗相关的严重副作用
** 包括本次交易在内的，该股今年以来累计上涨约14%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.